ACADIA Pharmaceuticals Files 8-K Report

Ticker: ACAD · Form: 8-K · Filed: Jun 10, 2025 · CIK: 1070494

Acadia Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyAcadia Pharmaceuticals Inc (ACAD)
Form Type8-K
Filed DateJun 10, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, other-events

Related Tickers: ACAD

TL;DR

ACADIA filed an 8-K, no major news yet.

AI Summary

On June 9, 2025, ACADIA Pharmaceuticals Inc. filed an 8-K report to disclose other events. The filing does not contain specific details regarding material events, agreements, or financial transactions beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates that ACADIA Pharmaceuticals Inc. has made a regulatory submission, but it does not provide details on any significant new developments or events.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or events.

Key Players & Entities

  • ACADIA Pharmaceuticals Inc. (company) — Registrant
  • June 9, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 000-50768 (filing_id) — SEC File Number
  • 06-1376651 (tax_id) — IRS Employer Identification No.
  • 12830 El Camino Real, Suite 400 (address) — Principal Executive Offices
  • San Diego, California (location) — Principal Executive Offices City and State
  • 92130 (zip_code) — Principal Executive Offices Zip Code
  • (858) 558-2871 (phone_number) — Registrant's Telephone Number

FAQ

What is the purpose of this 8-K filing by ACADIA Pharmaceuticals Inc.?

The 8-K filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' as of June 9, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on June 9, 2025.

Where is ACADIA Pharmaceuticals Inc. incorporated?

ACADIA Pharmaceuticals Inc. is incorporated in Delaware.

What is the principal executive office address for ACADIA Pharmaceuticals Inc.?

The principal executive office address is 12830 El Camino Real, Suite 400, San Diego, California, 92130.

Does this 8-K filing disclose any specific material agreements or financial transactions?

No, this 8-K filing is categorized under 'Other Events' and does not provide specific details on material agreements or financial transactions within the provided text.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 regarding ACADIA PHARMACEUTICALS INC (ACAD).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.